


 <b>Birmingham and Solihull</b> Integrated Care Board		
---	--	--

### **Collaborative Working Project executive summary**

<b>Project Title</b>	A Collaborative Working Agreement between Sanofi and NHS Birmingham & Solihull ICB to review the COPD pathway and services across BSOL ICB by undertaking a pathway mapping and population health management approach to improve the identification and management of people with COPD.
<b>Partner organisation/s</b>	<b>NHS Birmingham &amp; Solihull ICB</b> , Alpha Tower Suffolk Street Queensway, Birmingham B1 1TT <b>Sanofi</b> , 410 Thames Valley Drive, Reading, Berkshire, RG6 1PT
<b>Project Rationale</b>	<p>There are 23,632 people diagnosed with COPD within the NHS Birmingham and Solihull (BSOL) ICB (March 2024 - QOF data). An additional 656 people were diagnosed with COPD in the year since March 2023 which is an increase of 2.9%. The prevalence of COPD is 1.45% which is below the England average of 1.86%. It is felt that this reflects the under diagnosis of COPD within the BSOL ICB (QOF data 2023-24). In 2023-24, there were 3,495 non-elective admissions to hospital with a primary diagnosis of COPD at a cost of £8,831,698. The COPD admission rate was 148 per 1,000 total population in 2023-24 which is higher than the England average of 113.</p> <p>This collaborative working project aims to gain information on the number of patients that meet the criteria on being introduced to advanced therapy, capacity and demand for specialist care, and where services are currently located in order to plan for service delivery. UHB also realises the potential of moving care into the community, raising the need to utilise locality models with integration of respiratory specialists whilst retaining speciality oversight of the advanced therapies.</p> <p>This project requires dedicated project management support, to work alongside UHB and ICB resources to map out the current service delivery and reviewing data to determine and design optimal COPD care for the population with COPD within the ICB. Sanofi will provide dedicated project management capacity to support the review of existing pathway and services working with clinicians and commissioners.</p>
<b>Project Period</b>	Q4 2025 – Q2 2026
<b>Project Objectives</b>	<p>The <b>aim</b> of the collaborative working project is to review the COPD pathway and services across BSOL ICB by undertaking a pathway mapping and population health management approach to improve the identification and management of patients.</p> <p>The <b>objectives</b> of the project are to:</p> <ul style="list-style-type: none"> <li>• Undertake a review and deep dive of the COPD service/pathway within the ICB to:</li> </ul>

	<ul style="list-style-type: none"> <li>○ Assess how the COPD service and pathway meets the standards of the NICE guidelines, 5 core standards of care and national best practice and national priorities through:</li> <li>○ Benchmark against comparative national and local data (e.g., NRAP, GIRFT Review, Model Health System)</li> <li>○ Undertake interviews with key stakeholders to obtain their views on the current pathway/service to identify gaps and issues and make recommendations on pathway changes to address them.</li> <li>• Undertake a population health management approach utilising primary and secondary care data sources to describe to review the population with COPD and their access to treatment and outcomes and identify variation in care and develop proposals to address this variation:             <ul style="list-style-type: none"> <li>○ COPD diagnosis and prevalence in primary care including geographical variation</li> <li>○ Management of COPD in primary care including annual reviews and referrals for pulmonary rehabilitation.</li> <li>○ Review receipt of optimal care and uptake of preventative interventions within the population with COPD including flu and pneumonia immunisation, pulmonary rehabilitation, smoking cessation with analyses against geography and through a health inequalities lens (sociodemographic subgroups) including:                 <ul style="list-style-type: none"> <li>▪ Smoking cessation (offered and quit rates) for all current smokers.</li> <li>▪ Pulmonary rehab (offered and completed) for all patients who have MRC breathlessness score <math>\geq 2</math>.</li> <li>▪ LAMA/LABA uptake within COPD population.</li> </ul> </li> <li>○ Analyse data on A&amp;E attendances, hospital admissions and subsequent follow-up to assess the level of specialist follow-up for patients with COPD. Based on findings of the data analysis to identify any changes to the pathway that are required to optimise treatment A&amp;E attendance or hospital admission.</li> <li>○ Identify health inequalities within the current pathway/services for people with COPD and review what services are currently doing to tackle health inequalities and particularly to meet the Core20Plus5 respiratory targets.</li> </ul> </li> <li>• Review the capacity and demand for COPD specialist clinics and review and identify the service requirements to deliver advanced therapies in the current pathway.</li> <li>• Review opportunities for improving the integration of respiratory care for COPD patients across primary, community and secondary care.</li> <li>• Develop a report on the outcomes of the review with recommendations to improve the pathway and service for patients with COPD, implement interventions at a population health level,</li> </ul>
--	---

 <p><b>Birmingham and Solihull</b> Integrated Care Board</p>		
	<p>improve efficiency of existing services and reduce health inequalities for people with COPD.</p> <ul style="list-style-type: none"> <li>• Develop an outline Action Plan to implement agreed pathway and service changes and Evaluation Framework to support the evaluation of the agreed changes.</li> </ul> <p>The collaborative working project will aim to deliver the following potential benefits for Patients, the NHS and Sanofi:</p> <p><b><u>Patients:</u></b></p> <ul style="list-style-type: none"> <li>• To ensure equity of pathway access, provision, and experience for patients with COPD in the ICB.</li> <li>• More equitable access to care for patients with COPD.</li> <li>• Better access to treatment options for patients with COPD as well as a clear pathway of care with an improved patient experience.</li> </ul> <p><b><u>NHS:</u></b></p> <ul style="list-style-type: none"> <li>• Improved pathway for patients with COPD.</li> <li>• Address health inequalities by reduction in unwarranted variations in care for patients with COPD.</li> <li>• Increase in patients with COPD receiving specialist review in a timely manner through improved identification, referral from primary care and follow-up and treatment optimisation after A&amp;E attendance and hospital admission.</li> <li>• Implementation of an improved and more efficient pathway for patients with COPD that is in line with NICE guidance.</li> </ul> <p><b><u>Sanofi:</u></b></p> <ul style="list-style-type: none"> <li>• A better understanding of the COPD services within the BSOL ICB/ UHB Trust.</li> <li>• Improved corporate reputation within the Trust and partner organisations by supporting them to improve the quality of care for patients with COPD.</li> <li>• Understanding of how a population health management approach can be used to improve patient care.</li> <li>• As a result of pathway changes some appropriate patients in the future may be prescribed Sanofi products in line with NICE guidance.</li> </ul> <p>This project will be supported by pooling resources of approximately £11,500 (Sanofi 49%, NHS 51%)</p>	
<p><b>Contact Details</b></p>	<p><b>NHS Birmingham &amp; Solihull Integrated Care Board</b> - Andrew McKirgan - Director of Community Care</p> <p>Tel: 0121 203 3300.</p>	

 <p><b>Birmingham and Solihull</b> Integrated Care Board</p>		
--	--	--

	<p><b>Sanofi - Paul Naish – Head of Market Access UKIE</b>  <a href="mailto:GB-MarketAccess@sanofi.com">GB-MarketAccess@sanofi.com</a></p>
--	--